Non-Small Cell Lung Cancer: key endpoint results by drug

The key endpoints of Non-Small Cell Lung Cancer trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Non-Small Cell Lung Cancer page.

PFS, median

PFS, median in Non-Small Cell Lung Cancer: 54 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib3.61.9 (Erlotinib)—n 270NCT02152631 Phase 3, secondary
Afatinib11.26.9 (Pemetrexed/Cisplatin)—40 mg · n 230NCT00949650 Phase 3, primary
Alectinib10.91.4 (Premetrexed/Docetaxel)—n 79NCT02604342 Phase 3, primary
Alymsys (bevacizumab-maly)8.38.6 (Avastin)—wk 52 · n 315NCT03296163 Phase 3, secondary
Amivantamab23.716.6 (Osimertinib)—n 429NCT04487080 Phase 3, primary
Atezolizumab75.5 (Nab-Paclitaxel+Carboplatin)—n 456NCT02367781 Phase 3, primary
Bevacizumab4.83.7+1.1n 370NCT00257608 Phase 3, primary
bevacizumab-awwb6.67.9 (Bevacizumab)—n 328NCT01966003 Phase 3, secondary
Brigatinib24.011.1 (Crizotinib)—90 mg QD/180 QD · n 137NCT02737501 Phase 3, primary
Cabozantinib4.64 (Docetaxel)—n 186NCT04471428 Phase 3, secondary
Camrelizumab11.3a8.3 (carboplatin + pemetrexed alone, PC)——NCT03134872 Phase 3, primary
Capmatinib6.14.1 (Docetaxel)—n 15NCT04427072 Phase 3, primary
Cemiplimab6.35.3 (Chemotherapy)—n 357NCT03088540 Phase 3, primary
Ceritinib16.68.1 (Chemotherapy)—n 189NCT01828099 Phase 3, primary
Crizotinib7.73 (Chemotherapy)—n 173NCT00932893 Phase 3, primary
Dacomitinib PF-0029980414.79.2 (Gefitinib)—n 227NCT01774721 Phase 3, primary
Datopotamab Deruxtecan4.43.7 (Docetaxel)—6.0 mg/kg · n 299NCT04656652 Phase 3, primary
Dostarlimab4.44.1 (Docetaxel)—n 305NCT04655976 Phase 2/3, secondary
Durvalumab16.85.6+11.2n 476NCT02125461 Phase 3, primary
Erlotinib7.66+1.6n 226NCT00883779 Phase 3, primary
Gefitinib5.45.4±0n 133NCT01544179 Phase 3, primary
Gemcitabine5.15.5 (Chemotherapy)—n 396NCT02477826 Phase 3, primary
Icotinib4.63.4 (Gefitinib)—n 199NCT01040780 Phase 3, primary
Ipilimumab5.15.5 (Chemotherapy)—n 396NCT02477826 Phase 3, primary
Ixabepilone6.75.3 (Ixabepilone/Carboplatin)—n 40NCT00741988 Phase 2, secondary
Lazertinib20.69.7 (Gefitnib)—240 mg · n 196NCT04248829 Phase 3, primary
Nab-paclitaxel3.12.6+0.5n 136NCT02027428 Phase 3, primary
Necitumumab5.75.5 (Gemcitabine + Cisplatin)—n 545NCT00981058 Phase 3, secondary
Niraparib5.55.5±0n 200NCT04475939 Phase 3, primary
Nivolumab12.18.1+4n 275NCT03117049 Phase 3, primary
Oleclumab21.17.3 (Durvalumab Monotherapy)—n 60NCT03822351 Phase 2, secondary
Osimertinib19.522.0 (Gefitinib)—n 45NCT02856893 Phase 2, secondary
Pembrolizumab8.84.9+3.9n 410NCT02578680 Phase 3, primary
Penpulimab8.6a4.2+4.4—NCT03866993 Phase 3, primary
Pralsetinib18.79 (SOC)—n 110NCT04222972 Phase 3, primary
Ramucirumab4.53+1.5n 628NCT01168973 Phase 3, secondary
Savolitinib8.2a4.5 (chemotherapy)——NCT05015608 Phase 3, primary
Selpercatinib24.811.2 (Pemetrexed and Platinum With Pembrolizumab)—n 129NCT04194944 Phase 3, primary
Sintilimab8.95+3.9n 266NCT03607539 Phase 3, primary
Sotorasib5.64.5 (Docetaxel)—n 171NCT04303780 Phase 3, primary
Tepotinib4.94.4 (Pemetrexed and Cisplatin/Carboplatin)—500 mg + 250 mg · n 31NCT01982955 Phase 1/2, primary
Tislelizumab7.65.5 (Paclitaxel + Carboplatin)—n 120NCT03594747 Phase 3, primary
Toripalimab8.4a5.6+2.8—NCT03856411 Phase 3, primary
Trametinib2.72.6 (Docetaxel)—2 mg · n 86NCT01362296 Phase 2, primary
Tremelimumab3.95.4 (SoC Chemotherapy)—n 163NCT02453282 Phase 3, primary
Avelumab2.7b——n 42NCT04173507 Phase 2, secondary
Cetuximab11.9b——n 83NCT02438722 Phase 2/3, primary
Dabrafenib10.2b——DAB 150MG BID, TRA 2mG QD · n 48NCT01336634 Phase 2, secondary
Enfortumab Vedotin5.4b——n 45NCT04225117 Phase 2, secondary
Lorlatinib16.6b——n 30NCT01970865 Phase 1/2, secondary
Nogapendekin alfa inbakicept (Anktiva)5.8b——n 23NCT02523469 Phase 1/2, secondary
Olaparib7.1b——n 337NCT03976323 Phase 3, primary
pemetrexed8.4b——n 118NCT01017874 Phase 3, primary
Trastuzumab Deruxtecan9.5b——6.4 mg/kg · n 50NCT04644237 Phase 2, secondary

Drugs checked with no result here: 47 trial running, 38 not reported, 4 not posted.

OS, median

OS, median in Non-Small Cell Lung Cancer: 45 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib7.47.8 (Erlotinib)—n 270NCT02152631 Phase 3, primary
Afatinib28.228.2 (Pemetrexed/Cisplatin)—40 mg · n 230NCT00949650 Phase 3, secondary
Alectinib81.154.2 (Crizotinib)—n 152NCT02075840 Phase 3, secondary
Atezolizumab13.89.6 (Docetaxel)—n 425NCT02008227 Phase 3, primary
Bevacizumab9.39.2+0.1n 319NCT00130728 Phase 3, primary
Cabozantinib10.710.5 (Docetaxel)—n 186NCT04471428 Phase 3, primary
Capmatinib12.513.6 (Docetaxel)—n 15NCT04427072 Phase 3, secondary
Cemiplimab21.112.9+8.2n 312NCT03409614 Phase 3, primary
Ceritinib62.940.7 (Chemotherapy)—n 189NCT01828099 Phase 3, secondary
Crizotinib21.721.9 (Chemotherapy)—n 173NCT00932893 Phase 3, secondary
Dacomitinib PF-002998046.86.3+0.5n 480NCT01000025 Phase 3, primary
Datopotamab Deruxtecan12.911.8 (Docetaxel)—6.0 mg/kg · n 299NCT04656652 Phase 3, primary
Dostarlimab11.911.3 (Docetaxel)—n 305NCT04655976 Phase 2/3, primary
Durvalumab11.78.7 (SoC)—n 62NCT02352948 Phase 3, primary
Erlotinib11.910.2 (Standard of Care)—n 245NCT01351415 Phase 3, primary
Gefitinib14.817.2−2.4n 133NCT01544179 Phase 3, secondary
Gemcitabine85.8——n 752NCT00324805 Phase 3, primary
Icotinib13.313.9 (Gefitinib)—n 199NCT01040780 Phase 3, secondary
Ipilimumab13.412.4+0.9n 388NCT01285609 Phase 3, primary
Ixabepilone13.29.3 (Ixabepilone/Carboplatin)—n 40NCT00741988 Phase 2, secondary
Nab-paclitaxel14.213.5 (Nab-Paclitaxel + Carboplatin)—n 343NCT02367794 Phase 3, primary
Necitumumab11.59.9 (Gemcitabine + Cisplatin)—n 545NCT00981058 Phase 3, primary
Niraparib24.832.5−7.7n 200NCT04475939 Phase 3, secondary
Nivolumab12.29.4 (Docetaxel)—n 292NCT01673867 Phase 3, primary
Pembrolizumab15.911.3+4.6n 278NCT02775435 Phase 3, primary
Ramucirumab10.59.1+1.4n 628NCT01168973 Phase 3, primary
Selpercatinib33.0——n 159NCT04194944 Phase 3, secondary
Sintilimab11.88.3 (Docetaxel)—n 145NCT03150875 Phase 3, primary
Tepotinib17.319.5 (Pemetrexed and Cisplatin/Carboplatin)—500 mg + 250 mg · n 31NCT01982955 Phase 1/2, secondary
Tislelizumab26.119.4 (Paclitaxel + Carboplatin)—n 120NCT03594747 Phase 3, secondary
Trametinib8.19.9 (Docetaxel)—2 mg · n 86NCT01362296 Phase 2, secondary
Tremelimumab11.916.3 (Durvalumab)—n 163NCT02453282 Phase 3, primary
Avelumab7.6b——n 42NCT04173507 Phase 2, secondary
Brigatinib25.9b——90 mg · n 112NCT02094573 Phase 2, secondary
Cetuximab9.5b——n 233NCT00828841 Phase 2, primary
Dabrafenib18.2b——DAB 150MG BID, TRA 2mG QD · n 49NCT01336634 Phase 2, secondary
Lazertinib9.1b——240 mg · n 11NCT04075396 Phase 1/2, secondary
Lorlatinib52.5b——n 27NCT01970865 Phase 1/2, secondary
Nogapendekin alfa inbakicept (Anktiva)12.4b——n 23NCT02523469 Phase 1/2, secondary
Olaparib20.7b——n 337NCT03976323 Phase 3, primary
pemetrexed26.9b——n 118NCT01017874 Phase 3, secondary
Pralsetinib39.7b——n 141NCT03037385 Phase 1/2, secondary
Sasanlimab14.7b——300 mg SC · n 68NCT02573259 Phase 1, secondary
Sotorasib12.4b——200 mg BIW D1D2 + 960 mg QD · n 43NCT05054725 Phase 2, secondary
Trastuzumab Deruxtecan17.9b——6.4 mg/kg · n 50NCT04644237 Phase 2, secondary

Drugs checked with no result here: 48 trial running, 41 not reported, 9 not posted.

ORR

ORR in Non-Small Cell Lung Cancer: 52 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abemaciclib8.9%2.7% (Erlotinib)—n 270NCT02152631 Phase 3, secondary
Afatinib67.8%23% (Gemcitabine / Cisplatin)—40mg · n 242NCT01121393 Phase 3, secondary
Alectinib82.9%75.5% (Crizotinib)—n 152NCT02075840 Phase 3, secondary
Alymsys (bevacizumab-maly)40.3%44.6% (Avastin)—wk 18 · n 315NCT03296163 Phase 3, primary
Atezolizumab11%10.5% (Atezolizumab IV)—1875 mg · n 245NCT03735121 Phase 3, secondary
Bevacizumab47.6%42.8% (Bevacizumab (Avastin))—wk 24 · n 379NCT02754882 Phase 3, primary
bevacizumab-awwb39%41.7% (Bevacizumab)—n 328NCT01966003 Phase 3, primary
Brigatinib74.5%62.3% (Crizotinib)—90 mg QD/180 QD · n 137NCT02737501 Phase 3, secondary
Cabozantinib11.8%13.3% (Docetaxel)—n 186NCT04471428 Phase 3, secondary
Capmatinib53.3%0% (Docetaxel)—n 15NCT04427072 Phase 3, secondary
Cemiplimab43.6%22.1%+21.5n 312NCT03409614 Phase 3, secondary
Ceritinib72.5%26.7% (Chemotherapy)—n 189NCT01828099 Phase 3, secondary
Crizotinib65.3%19.5% (Chemotherapy)—n 173NCT00932893 Phase 3, secondary
Dacomitinib PF-002998047.1%1.3%+5.8n 480NCT01000025 Phase 3, secondary
Dostarlimab18.7%14.5% (Docetaxel)—n 305NCT04655976 Phase 2/3, secondary
Durvalumab60.7%60.6%+0.1n 219NCT03519971 Phase 3, secondary
Erlotinib42.9%17.8%+25.1n 226NCT00883779 Phase 3, secondary
Gefitinib31.6%34.1%−2.5n 133NCT01544179 Phase 3, secondary
Gemcitabine36.4%29.7% (Chemotherapy)—n 396NCT02477826 Phase 3, secondary
Ipilimumab36.4%29.7% (Chemotherapy)—n 396NCT02477826 Phase 3, secondary
Ixabepilone50%29% (Ixabepilone/Carboplatin)—wk 78 · n 36NCT00741988 Phase 2, primary
Lazertinib76%76.1% (Gefitnib)—240 mg · n 196NCT04248829 Phase 3, secondary
Lorlatinib75.8%57.8% (Crizotinib)—n 149NCT03052608 Phase 3, secondary
Nab-paclitaxel33%25% (Paclitaxel)—n 521NCT00540514 Phase 3, primary
Necitumumab31.2%28.8% (Gemcitabine + Cisplatin)—n 545NCT00981058 Phase 3, secondary
Nivolumab61.5%50.5%+11n 275NCT03117049 Phase 3, secondary
Oleclumab35%23.9% (Durvalumab Monotherapy)—wk 16 · n 60NCT03822351 Phase 2, primary
Pembrolizumab47.6%18.9%+28.7n 410NCT02578680 Phase 3, secondary
Pembrolizumab berahyaluronidase alfa64.3%18.2% (Pembrolizumab)—n 28NCT06212752 Phase 3, primary
Pralsetinib65.5%41.6% (SOC)—n 110NCT04222972 Phase 3, secondary
Ramucirumab22.9%13.6%+9.3n 628NCT01168973 Phase 3, secondary
Relatlimab50.6%43% (Nivolumab + Chemotherapy)—wk 64 · n 158NCT04623775 Phase 2, primary
Selpercatinib83.7%65.1% (Pemetrexed and Platinum With Pembrolizumab)—n 129NCT04194944 Phase 3, secondary
Sintilimab51.9%29.8%+22.1n 266NCT03607539 Phase 3, secondary
Tepotinib45.2%33.3% (Pemetrexed and Cisplatin/Carboplatin)—500 mg + 250 mg · n 31NCT01982955 Phase 1/2, secondary
Tislelizumab74.2%47.9% (Paclitaxel + Carboplatin)—n 120NCT03594747 Phase 3, secondary
Tremelimumab34.4%35.6% (Durvalumab)—n 163NCT02453282 Phase 3, secondary
Zirabev (bevacizumab-bvzr)45.3%44.6% (Bevacizumab-EU)—wk 25 · n 358NCT02364999 Phase 3, primary
Apatinib16.7%b——375 mg · n 12NCT03083041 Phase 2, primary
Avelumab2%b——n 42NCT04173507 Phase 2, primary
Binimetinib74.6%b——n 59NCT03915951 Phase 2, primary
Camrelizumab16.7%b——375 mg · n 12NCT03083041 Phase 2, primary
Cetuximab67%b——n 76NCT02438722 Phase 2/3, secondary
Datopotamab Deruxtecan35.8%b——6.0 mg/kg Q3W · n 137NCT04484142 Phase 2, primary
Encorafenib74.6%b——n 59NCT03915951 Phase 2, primary
Enfortumab Vedotin39%b——n 41NCT04225117 Phase 2, primary
Niraparib56.3%b——n 16NCT03308942 Phase 2, primary
Osimertinib76%b——n 25NCT02789345 Phase 1, secondary
pemetrexed41.5%b——n 118NCT01017874 Phase 3, secondary
Sasanlimab16.4%b——300 mg SC · n 67NCT02573259 Phase 1, primary
Savolitinib62.1%ab———NCT04923945 Phase 3, primary
Trastuzumab Deruxtecan56%b——6.4 mg/kg · n 50NCT04644237 Phase 2, primary

Drugs checked with no result here: 47 trial running, 36 not reported, 8 not posted.

Duration of response, median

Duration of response, median in Non-Small Cell Lung Cancer: 42 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Afatinib9.74.3 (Gemcitabine / Cisplatin)—40mg · n 164NCT01121393 Phase 3, secondary
Alectinib42.311.1 (Crizotinib)—n 126NCT02075840 Phase 3, secondary
Atezolizumab16.36.2 (Docetaxel)—n 58NCT02008227 Phase 3, secondary
Bevacizumab9.78.4+1.3n 38NCT00130728 Phase 3, secondary
bevacizumab-awwb5.85.6 (Bevacizumab)—n 128NCT01966003 Phase 3, secondary
Brigatinib33.113.8 (Crizotinib)—90 mg QD/180 QD · n 102NCT02737501 Phase 3, secondary
Cabozantinib5.54.3 (Docetaxel)—n 22NCT04471428 Phase 3, secondary
Capmatinib9.93.1 (Docetaxel)—n 7NCT04427072 Phase 3, secondary
Cemiplimab16.47.3+9.1n 136NCT03409614 Phase 3, secondary
Ceritinib23.911.1 (Chemotherapy)—n 137NCT01828099 Phase 3, secondary
Cetuximab4.84.8 (GCiC)—n 4NCT00870870 Phase 2, secondary
Crizotinib7.45.6 (Chemotherapy)—n 113NCT00932893 Phase 3, secondary
Dacomitinib PF-002998049.210.1 (Erlotinib)—n 52NCT01360554 Phase 3, secondary
Dostarlimab8.38.8 (Docetaxel)—n 57NCT04655976 Phase 2/3, secondary
Durvalumab30.718.6+12.1n 133NCT03519971 Phase 3, secondary
Erlotinib10.35.6+4.7n 97NCT00883779 Phase 3, secondary
Gemcitabine5.54.5 (Pem + Carb or Cis)—n 34NCT01160744 Phase 2, secondary
Ipilimumab25.825.2 (Durva)—n 194NCT04026412 Phase 3, secondary
Lazertinib19.48.3 (Gefitnib)—240 mg · n 196NCT04248829 Phase 3, secondary
Nab-paclitaxel9.69.5 (Paclitaxel)—n 170NCT00540514 Phase 3, secondary
Nivolumab117+4n 275NCT03117049 Phase 3, secondary
Oleclumab29.9——n 21NCT03822351 Phase 2, secondary
Pembrolizumab11.27.8+3.4n 195NCT02578680 Phase 3, secondary
Pralsetinib20.69.7 (SOC)—n 72NCT04222972 Phase 3, secondary
Ramucirumab12.95.6 (Standard of Care (Inv. Choice))—n 15NCT03971474 Phase 2, secondary
Relatlimab8.47.1 (Nivolumab + Chemotherapy)—n 158NCT04623775 Phase 2, secondary
Selpercatinib24.211.5 (Pemetrexed and Platinum With Pembrolizumab)—n 108NCT04194944 Phase 3, secondary
Sintilimab6.05.1+1n 80NCT03629925 Phase 3, secondary
Tislelizumab8.44.3 (Paclitaxel + Carboplatin)—n 89NCT03594747 Phase 3, secondary
Trametinib1.62.9 (Docetaxel)—2 mg · n 10NCT01362296 Phase 2, secondary
Tremelimumab7.46 (D + SoC)—n 155NCT03164616 Phase 3, secondary
Zirabev (bevacizumab-bvzr)8.46.6 (Bevacizumab-EU)—n 162NCT02364999 Phase 3, secondary
Avelumab7.3b——n 1NCT04173507 Phase 2, secondary
Dabrafenib9.8b——DAB 150MG BID, TRA 2mG QD · n 39NCT01336634 Phase 2, secondary
Enfortumab Vedotin7.2b——n 7NCT04225117 Phase 2, secondary
Lorlatinib20.9b——n 26NCT04362072 Phase 4, secondary
Niraparib22.8b——n 9NCT03308942 Phase 2, secondary
Nogapendekin alfa inbakicept (Anktiva)4.6b——n 1NCT02523469 Phase 1/2, secondary
Osimertinib13.4b——n 19NCT02789345 Phase 1, secondary
pemetrexed12.1b——n 49NCT01017874 Phase 3, secondary
Sotorasib12.2b——200 mg BIW D1D2 + 960 mg QD · n 11NCT05054725 Phase 2, secondary
Trastuzumab Deruxtecan12.9b——6.4 mg/kg · n 28NCT04644237 Phase 2, secondary

Drugs checked with no result here: 50 trial running, 40 not reported, 11 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 143 approved or late-stage drugs with a featured trial in Non-Small Cell Lung Cancer were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.